CDMO, CMO, Supplier Roundup in Supporting COVID-19 Projects
The latest from CDMOs/CMOs and suppliers in COVID-19 projects featuring Batavia Biosciences and Swissfillon.
Biologics Manufacturing
Batavia Biosciences, RocketVax in Pact for COVID-19 Vaccine
Batavia Biosciences, a Leiden, the Netherlands-based CDMO, and RocketVax, a Basel, Switzerland-based bio/pharmaceutical company, have entered into a collaboration to develop vaccines based on breakthrough genetic engineering, including RocketVax’s vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
RocketVax is developing a second-generation COVID-19 vaccine candidate, RVX-13, which comprises of all immunogenic features of SARS-CoV-2. RocketVax aims to start the Phase I clinical trials in the second quarter of 2022.
Under the agreement, Batavia will develop the clinical process able to deliver 1,000 doses of material for clinical trials and deliver clinical product of RVX-13. Batavia will deploy its HIP-Vax manufacturing technology to deliver a scalable process for the product.
Source: Batavia Biosciences and RocketVax
Formulation Development/Drug-Product Manufacturing
Swissfillon Supplies Swiss Gov’t with Materials for COVID-19 Test Kits
Swissfillon, a Visp, Switzerland-based drug-product CDMO specializing in sterile filling, has supplied 0.8 million aseptically filled transport media in syringes for the Swiss Army Pharmacy’s COVID-19 PCR test kit.
The syringes are filled aseptically on the company’s isolator filling line. This line is also used for filling sterile injectables, which is Swissfillon’s core business.
In March 2020, Swissfillon was approached by the Swiss Army Pharmacy to provide testing capabilities for Switzerland. Swissfillon then developed and established a filling process for the transport medium, which the Swiss Army Pharmacy had procured from a Zurich-based company, KlusLab.
Source: Swissfillon
